The TOURMALINE-MM1 study will compare oral MLN9708 plus lenalidomide and dexamethasone to placebo plus lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. The randomized, double-blind,
The study will assess the safety and efficacy of TMC435 and daclatasvir in combination with or without Ribavirin in chronic genotype-1 hepatitis C infected patients who are treatment-naive
The finance bought 742,001 shares for Rs115.79 per share on NSE. Macquarie Bank and ABN Amro Bank have sold around 366,000 and 355,485 shares respectively for Rs115.71 on
Veletri (epoprostenol) for injection is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Actelion Pharmaceuticals president Shal Jacobovitz said, "Second
The biotechnology company will use CLIA waived Piccolo Xpress instruments in the course of conducting a four-year drug clinical trial. Abaxis chairman and CEO Clint Severson said an
MM-398 is designed to optimise the delivery of irinotecan by extending the duration of circulation in the body and preferentially activating the drug within the tumour to achieve
Voclosporin is a new generation calcineurin inhibitor licensed from Isotechnika Pharma. According to the approved protocol, the study will be a Phase III, randomized, multi-center, concentration-controlled comparison study
The voluntary recall is being conducted due to the discovery of particulate matter, which has been recognized as a potential health hazard, in a small number of vials
Myrbetriq is a once daily oral beta-3 adrenergic agonist discovered and developed by Astellas. Astellas Pharma Global Development president Steven Ryder said, "Myrbetriq is the first oral OAB
In the two step Phase 1 trial, perifosine is combined with bortezomib (Velcade) and dexamethasone in patients with refractory multiple myeloma who were previously treated with bortezomib. Aeterna
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.